Top

Cancer Cell International

Published in:

Open Access 01-12-2021 | Glioblastoma | Hypothesis

Proteo-transcriptomics meta-analysis identifies SUMO2 as a promising target in glioblastoma multiforme therapeutics

Authors: Aswani P. Krishna, Sebastian John, Puja Laxmanrao Shinde, Rashmi Mishra

Published in: Cancer Cell International | Issue 1/2021

Abstract

Background

Glioblastoma multiforme (GBM) is a deadly brain tumour with minimal survival rates due to the ever-expanding heterogeneity, chemo and radioresistance. Kinases are known to crucially drive GBM pathology; however, a rationale therapeutic combination that can simultaneously inhibit multiple kinases has not yet emerged successfully.

Results

Here, we analyzed the GBM patient data from several publicly available repositories and deduced hub GBM kinases, most of which were identified to be SUMOylated by SUMO2/3 isoforms. Not only the hub kinases but a significant proportion of GBM upregulated genes involved in proliferation, metastasis, invasion, epithelial-mesenchymal transition, stemness, DNA repair, stromal and macrophages maintenance were also identified to be the targets of SUMO2 isoform. Correlatively, high expression of SUMO2 isoform was found to be significantly associated with poor patient survival.

Conclusions

Although many natural products and drugs are evidenced to target general SUMOylation, however, our meta-analysis strongly calls for the need to design SUMO2/3 or even better SUMO2 specific inhibitors and also explore the SUMO2 transcription inhibitors for universally potential, physiologically non-toxic anti-GBM drug therapy.

Graphical Abstract

Available only for authorised users

Zhou A. Targeting protein kinases for the treatment of glioblastoma multiforme: linking basic studies to clinical applications. Curr Pharm Des. 2017;23:4290–302. https://doi.org/10.2174/1381612823666170710144325.CrossRefPubMed

Pearson JRD, Regad T. Targeting cellular pathways in glioblastoma multiforme. Signal Transduct Target Ther. 2017;2:17040. https://doi.org/10.1038/sigtrans.2017.40.CrossRefPubMedPubMedCentral

Sathornsumetee S, Reardon DA. Targeting multiple kinases in glioblastoma multiforme. Expert Opin Investig Drugs. 2009;18:277–92. https://doi.org/10.1517/13543780802692603.CrossRefPubMed

Radivojac P, Baenziger PH, Kann MG, Mort ME, Hahn MW, Mooney SD. Gain and loss of phosphorylation sites in human cancer. Bioinformatics. 2008;24:i241–7. https://doi.org/10.1093/bioinformatics/btn267.CrossRefPubMedPubMedCentral

Bleeker FE, Lamba S, Zanon C, Molenaar RJ, Hulsebos TJM, Troost D, van Tilborg AA, Vandertop WP, Leenstra S, van Noorden CJF, et al. Mutational profiling of kinases in glioblastoma. BMC Cancer. 2014;14:718. https://doi.org/10.1186/1471-2407-14-718.CrossRefPubMedPubMedCentral

Zhao JJ, Roberts TM. PI3 kinases in cancer: from oncogene artifact to leading cancer target. Sci STKE. 2006. https://doi.org/10.1126/stke.3652006pe52.CrossRefPubMed

Albert L, Karsy M, Murali R, Jhanwar-Uniyal M. Inhibition of mTOR activates the MAPK pathway in glioblastoma multiforme. Cancer Genomics Proteomics. 2009;6:255–61.PubMed

Peña-Ortiz MÁ, Germán-Castelán L, González-Arenas A. Growth factors and kinases in glioblastoma growth. Adv Mod Oncol Res. 2016;2(5):248–60.CrossRef

Hendriks IA, D’Souza RCJ, Yang B, Verlaan-de Vries M, Mann M, Vertegaal ACO. Uncovering global SUMOylation signaling networks in a site-specific manner. Nat Struct Mol Biol. 2014;21:927–36. https://doi.org/10.1038/nsmb.2890.CrossRefPubMedPubMedCentral

10.

Kukkula A, Ojala VK, Mendez LM, Sistonen L, Elenius K, Sundvall M. Therapeutic potential of targeting the SUMO pathway in cancer. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13174402.CrossRef

11.

Fox BM, Janssen A, Estevez-Ordonez D, Gessler F, Vicario N, Chagoya G, Elsayed G, Sotoudeh H, Stetler W, Friedman GK, et al. SUMOylation in glioblastoma: a novel therapeutic target. Int J Mol Sci. 2019;20:1853. https://doi.org/10.3390/ijms20081853.CrossRefPubMedCentral

12.

Yang W, Wang L, Roehn G, Pearlstein RD, Ali-Osman F, Pan H, Goldbrunner R, Krantz M, Harms C, Paschen W. Small ubiquitin-like modifier 1–3 conjugation [corrected] is activated in human astrocytic brain tumours and is required for glioblastoma cell survival. Cancer Sci. 2013;104:70–7. https://doi.org/10.1111/cas.12047.CrossRefPubMed

13.

Bellail AC, Olson JJ, Hao C. SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression. Nat Commun. 2014;5:4234. https://doi.org/10.1038/ncomms5234.CrossRefPubMed

14.

Wang L, Zhang J, Banerjee S, Barnes L, Barnes L, Sajja V, Liu Y, Guo B, Du Y, Agarwal MK, et al. Sumoylation of vimentin354 is associated with PIAS3 inhibition of glioma cell migration. Oncotarget. 2010;1:620–7. https://doi.org/10.18632/oncotarget.101101.CrossRefPubMedPubMedCentral

15.

Wang L, Ji S. Inhibition of Ubc9-induced CRMP2 SUMOylation disrupts glioblastoma cell proliferation. J Mol Neurosci. 2019;69:391–8. https://doi.org/10.1007/s12031-019-01368-y.CrossRefPubMed

16.

Erazo T, Espinosa-Gil S, Diéguez-Martínez N, Gómez N, Lizcano JM. SUMOylation is required for ERK5 nuclear translocation and ERK5-mediated cancer cell proliferation. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21062203.CrossRefPubMedPubMedCentral

17.

Sehat B, Tofigh A, Lin Y, Trocmé E, Liljedahl U, Lagergren J, Larsson O. SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal. 2010;3:ra10. https://doi.org/10.1126/scisignal.2000628.CrossRefPubMed

18.

Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med. 2011;12:419–32.PubMedPubMedCentral

19.

Mei L, Yuan L, Shi W, Fan S, Tang C, Fan X, Yang W, Qian Y, Hussain M, Wu X. SUMOylation of large tumour suppressor 1 at Lys751 attenuates its kinase activity and tumour-suppressor functions. Cancer Lett. 2017;386:1–11. https://doi.org/10.1016/j.canlet.2016.11.009.CrossRefPubMed

20.

He X, Li C, Ke R, Luo L, Huang D. Down-regulation of adenosine monophosphate-activated protein kinase activity: a driver of cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2017;39:1010428317697576. https://doi.org/10.1177/1010428317697576.CrossRef

21.

Nakagawa S, Koricheva J, Macleod M, Viechtbauer W. Introducing our series: research synthesis and meta-research in biology. BMC Biol. 2020;18:20. https://doi.org/10.1186/s12915-020-0755-0.CrossRefPubMedPubMedCentral

22.

Eid S, Turk S, Volkamer A, Rippmann F, Fulle S. KinMap: a web-based tool for interactive navigation through human kinome data. BMC Bioinformatics. 2017;18:16. https://doi.org/10.1186/s12859-016-1433-7.CrossRefPubMedPubMedCentral

23.

Wilson LJ, Linley A, Hammond DE, Hood FE, Coulson JM, MacEwan DJ, Ross SJ, Slupsky JR, Smith PD, Eyers PA, et al. New perspectives, opportunities, and challenges in exploring the human protein kinome. Cancer Res. 2018;78:15–29. https://doi.org/10.1158/0008-5472.CAN-17-2291.CrossRefPubMed

24.

Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675–8. https://doi.org/10.1038/s41587-020-0546-8.CrossRefPubMedPubMedCentral

25.

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https://doi.org/10.1186/s13059-014-0550-8.CrossRefPubMedPubMedCentral

26.

Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2018;47:D607–13. https://doi.org/10.1093/nar/gky1131.CrossRefPubMedCentral

27.

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504. https://doi.org/10.1101/gr.1239303.CrossRefPubMedPubMedCentral

28.

Assenov Y, Ramírez F, Schelhorn S-E, Lengauer T, Albrecht M. Computing topological parameters of biological networks. Bioinformatics. 2008;24:282–4. https://doi.org/10.1093/bioinformatics/btm554.CrossRefPubMed

29.

Chin C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8:S11. https://doi.org/10.1186/1752-0509-8-S4-S11.CrossRefPubMedPubMedCentral

30.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–50. https://doi.org/10.1073/pnas.0506580102.CrossRefPubMedPubMedCentral

31.

Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57. https://doi.org/10.1038/nprot.2008.211.CrossRef

32.

Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omi A J Integr Biol. 2012;16:284–7. https://doi.org/10.1089/omi.2011.0118.CrossRef

33.

Mizuno H, Kitada K, Nakai K, Sarai A. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics. 2009;2:18. https://doi.org/10.1186/1755-8794-2-18.CrossRefPubMedPubMedCentral

34.

Dempster JM, Rossen J, Kazachkova M, Pan J, Kugener G, Root DE, Tsherniak A. Extracting biological insights from the project achilles genome-scale CRISPR screens in cancer cell lines. BioRxiv. 2019. https://doi.org/10.1101/720243.CrossRef

35.

Tran AN, Dussaq AM, Kennell T, Willey CD, Hjelmeland AB. HPAanalyze: an R package that facilitates the retrieval and analysis of the Human Protein Atlas data. BMC Bioinform. 2019;20:463. https://doi.org/10.1186/s12859-019-3059-z.CrossRef

36.

Hendriks IA, Lyon D, Su D, Skotte NH, Daniel JA, Jensen LJ, Nielsen ML. Site-specific characterization of endogenous SUMOylation across species and organs. Nat Commun. 2018;9:2456. https://doi.org/10.1038/s41467-018-04957-4.CrossRefPubMedPubMedCentral

37.

Gill BJ, Pisapia DJ, Malone HR, Goldstein H, Lei L, Sonabend A, Yun J, Samanamud J, Sims JS, Banu M, et al. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc Natl Acad Sci. 2014;111:12550. https://doi.org/10.1073/pnas.1405839111.CrossRefPubMedPubMedCentral

38.

Klemm F, Maas RR, Bowman RL, Kornete M, Soukup K, Nassiri S, Brouland J-P, Iacobuzio-Donahue CA, Brennan C, Tabar V, et al. Interrogation of the microenvironmental landscape in brain tumours reveals disease-specific alterations of immune cells. Cell. 2020;181:1643-1660.e17. https://doi.org/10.1016/j.cell.2020.05.007.CrossRefPubMedPubMedCentral

39.

Mistry AM, Wooten DJ, Davis LT, Mobley BC, Quaranta V, Ihrie RA. Ventricular-Subventricular zone contact by glioblastoma is not associated with molecular signatures in bulk tumour data. Sci Rep. 2019;9:1842. https://doi.org/10.1038/s41598-018-37734-w.CrossRefPubMedPubMedCentral

40.

Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou M-F, de Tribolet N, Regli L, Wick W, Kouwenhoven MCM, et al. Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26:3015–24. https://doi.org/10.1200/JCO.2007.15.7164.CrossRefPubMed

41.

Stringer BW, Day BW, D’Souza RCJ, Jamieson PR, Ensbey KS, Bruce ZC, Lim YC, Goasdoué K, Offenhäuser C, Akgül S, et al. A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma. Sci Rep. 2019;9:4902. https://doi.org/10.1038/s41598-019-41277-z.CrossRefPubMedPubMedCentral

42.

Brabetz S, Leary SES, Gröbner SN, Nakamoto MW, Şeker-Cin H, Girard EJ, Cole B, Strand AD, Bloom KL, Hovestadt V, et al. A biobank of patient-derived pediatric brain tumour models. Nat Med. 2018;24:1752–61. https://doi.org/10.1038/s41591-018-0207-3.CrossRefPubMed

43.

Horita H, Law A, Hong S, Middleton K. A simple toolset to identify endogenous post-translational modifications for a target protein: a snapshot of the EGFR signaling pathway. Biosci Rep. 2017;37:1.CrossRef

44.

Lichti CF, Wildburger NC, Shavkunov AS, Mostovenko E, Liu H, Sulman EP, Nilsson CL. The proteomic landscape of glioma stem-like cells. EuPA Open Proteom. 2015;8:85–93. https://doi.org/10.1016/j.euprot.2015.06.008.CrossRef

45.

Kozuka-Hata H, Nasu-Nishimura Y, Koyama-Nasu R, Ao-Kondo H, Tsumoto K, Akiyama T, Oyama M. Global proteome analysis of glioblastoma stem cells by high-resolution mass spectrometry. Curr Top Pept Protein Res. 2012;13:1–47.CrossRef

46.

La Manno G, Siletti K, Furlan A, Gyllborg D, Vinsland E, Mossi Albiach A, Mattsson Langseth C, Khven I, Lederer AR, Dratva LM, et al. Molecular architecture of the developing mouse brain. Nature. 2021;596:92–6. https://doi.org/10.1038/s41586-021-03775-x.CrossRefPubMed

47.

Apostolov A, Litim-Mecheri I, Oravecz A, Goepp M, Kirstetter P, Marchal P, Ittel A, Mauvieux L, Chan S, Kastner P. Sumoylation inhibits the growth suppressive properties of ikaros. PLoS ONE. 2016;11: e0157767. https://doi.org/10.1371/journal.pone.0157767.CrossRefPubMedPubMedCentral

48.

Morris JR. SUMO in the mammalian response to DNA damage. Biochem Soc Trans. 2010;38:92–7. https://doi.org/10.1042/BST0380092.CrossRefPubMed

49.

Christopoulos PF, Msaouel P, Koutsilieris M. The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer. 2015;14:43. https://doi.org/10.1186/s12943-015-0291-7.CrossRefPubMedPubMedCentral

50.

Abrieu A, Liakopoulos D. How Does SUMO Participate in Spindle Organization? Cells. 2019. https://doi.org/10.3390/cells8080801.CrossRefPubMedPubMedCentral

51.

Floris A, Mazarei M, Yang X, Robinson AE, Zhou J, Barberis A, et al. SUMOylation Protects FASN against proteasomal degradation in breast cancer cells treated with grape leaf extract. Biomolecules. 2020. https://doi.org/10.3390/biom10040529.CrossRefPubMedPubMedCentral

52.

Kobayashi T, Masoumi KC, Massoumi R. Deubiquitinating activity of CYLD is impaired by SUMOylation in neuroblastoma cells. Oncogene. 2015;34:2251–60. https://doi.org/10.1038/onc.2014.159.CrossRefPubMed

53.

Treuter E, Venteclef N. Transcriptional control of metabolic and inflammatory pathways by nuclear receptor SUMOylation. Biochim Biophys Acta. 2011;1812:909–18. https://doi.org/10.1016/j.bbadis.2010.12.008.CrossRefPubMed

54.

An S, Huang L, Miao P, Shi L, Shen M, Zhao X, Liu J, Huang G. Small ubiquitin-like modifier 1 modification of pyruvate kinase M2 promotes aerobic glycolysis and cell proliferation in A549 human lung cancer cells. Onco Targets Ther. 2018;11:2097–109. https://doi.org/10.2147/OTT.S156918.CrossRefPubMedPubMedCentral

55.

Sapir A, Tsur A, Koorman T, Ching K, Mishra P, Bardenheier A, Podolsky L, Bening-Abu-Shach U, Boxem M, Chou T-F, et al. Controlled sumoylation of the mevalonate pathway enzyme HMGS-1 regulates metabolism during aging. Proc Natl Acad Sci. 2014;111:E3880–9. https://doi.org/10.1073/pnas.1414748111.CrossRefPubMedPubMedCentral

56.

Birzu C, French P, Caccese M, Cerretti G, Idbaih A, Zagonel V, Lombardi G. Recurrent glioblastoma: from molecular landscape to new treatment perspectives. Cancers (Basel). 2020. https://doi.org/10.3390/cancers13010047.CrossRef

57.

Zhang L, Liu Z, Li J, Huang T, Wang Y, Chang L, Zheng W, Ma Y, Chen F, Gong X, et al. Genomic analysis of primary and recurrent gliomas reveals clinical outcome related molecular features. Sci Rep. 2019;9:16058. https://doi.org/10.1038/s41598-019-52515-9.CrossRefPubMedPubMedCentral

58.

Sturm D, Bender S, Jones DTW, Lichter P, Grill J, Becher O, Hawkins C, Majewski J, Jones C, Costello JF, et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer. 2014;14:92–107. https://doi.org/10.1038/nrc3655.CrossRefPubMedPubMedCentral

59.

Szymura SJ, Bernal GM, Wu L, Zhang Z, Crawley CD, Voce DJ, Campbell P-A, Ranoa DE, Weichselbaum RR, Yamini B. DDX39B interacts with the pattern recognition receptor pathway to inhibit NF-κB and sensitize to alkylating chemotherapy. BMC Biol. 2020;18:32. https://doi.org/10.1186/s12915-020-0764-z.CrossRefPubMedPubMedCentral

60.

Bernstock JD, Yang W, Ye DG, Shen Y, Pluchino S, Lee Y-J, Hallenbeck JM, Paschen W. SUMOylation in brain ischemia: Patterns, targets, and translational implications. J Cereb blood flow Metab Off J Int Soc Cereb Blood Flow Metab. 2018;38:5–16. https://doi.org/10.1177/0271678X17742260.CrossRef

61.

Yang W, Sheng H, Wang H. Targeting the SUMO pathway for neuroprotection in brain ischaemia. Stroke Vasc Neurol. 2016;1:101–7. https://doi.org/10.1136/svn-2016-000031.CrossRefPubMedPubMedCentral

62.

Gimple RC, Bhargava S, Dixit D, Rich JN. Glioblastoma stem cells: lessons from the tumour hierarchy in a lethal cancer. Genes Dev. 2019;33:591–609. https://doi.org/10.1101/gad.324301.119.CrossRefPubMedPubMedCentral

63.

Bogachek MV, Park JM, De Andrade JP, Lorenzen AW, Kulak MV, White JR, Gu VW, Wu VT, Weigel RJ. Inhibiting the SUMO pathway represses the cancer stem cell population in breast and colorectal carcinomas. Stem Cell Rep. 2016;7:1140–51. https://doi.org/10.1016/j.stemcr.2016.11.001.CrossRef

64.

Du L, Li Y-J, Fakih M, Wiatrek RL, Duldulao M, Chen Z, Chu P, Garcia-Aguilar J, Chen Y. Role of SUMO activating enzyme in cancer stem cell maintenance and self-renewal. Nat Commun. 2016;7:12326. https://doi.org/10.1038/ncomms12326.CrossRefPubMedPubMedCentral

65.

Lee JE, Kim JH. SUMO modification regulates the protein stability of NDRG1. Biochem Biophys Res Commun. 2015;459:161–5. https://doi.org/10.1016/j.bbrc.2015.02.090.CrossRefPubMed

66.

Yao Y, Lu Y, Chen W-C, Jiang Y, Cheng T, Ma Y, Lu L, Dai W. Cobalt and nickel stabilize stem cell transcription factor OCT4 through modulating its sumoylation and ubiquitination. PLoS ONE. 2014;9: e86620. https://doi.org/10.1371/journal.pone.0086620.CrossRefPubMedPubMedCentral

67.

Rodriguez V, Bailey R, Larion M, Gilbert MR. Retinoid receptor turnover mediated by sumoylation, ubiquitination and the valosin-containing protein is disrupted in glioblastoma. Sci Rep. 2019;9:16250. https://doi.org/10.1038/s41598-019-52696-3.CrossRefPubMedPubMedCentral

68.

Molfetta R, Zingoni A, Santoni A, Paolini R. Post-translational mechanisms regulating NK cell activating receptors and their ligands in cancer: potential targets for therapeutic intervention. Front Immunol. 2019;10:2557. https://doi.org/10.3389/fimmu.2019.02557.CrossRefPubMedPubMedCentral

69.

Stauffer JK, Scarzello AJ, Jiang Q, Wiltrout RH. Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections. Hepatology. 2012;56:1567–74. https://doi.org/10.1002/hep.25674.CrossRefPubMed

70.

Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata-Yanagimoto M, Taniguchi K. Inflammation-Induced Tumourigenesis and Metastasis. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22115421.CrossRefPubMedPubMedCentral

71.

Bogachek MV, De Andrade JP, Weigel RJ. Regulation of epithelial-mesenchymal transition through SUMOylation of transcription factors. Cancer Res. 2015;75:11–5. https://doi.org/10.1158/0008-5472.CAN-14-2824.CrossRefPubMed

72.

Wang L, Wu J, Song S, Chen H, Hu Y, Xu B, Liu J. Plasma Exosome-Derived Sentrin SUMO-specific protease 1: a prognostic biomarker in patients with osteosarcoma. Front Oncol. 2021;11: 625109. https://doi.org/10.3389/fonc.2021.625109.CrossRefPubMedPubMedCentral

73.

Yue Z, Li C, Voth GA, Swanson JMJ. Dynamic protonation dramatically affects the membrane permeability of drug-like molecules. J Am Chem Soc. 2019;141:13421–33. https://doi.org/10.1021/jacs.9b04387.CrossRefPubMedPubMedCentral

74.

Adams DJ, Morgan LR. Tumour physiology and charge dynamics of anticancer drugs: implications for camptothecin-based drug development. Curr Med Chem. 2011;18:1367–72. https://doi.org/10.2174/092986711795029609.CrossRefPubMedPubMedCentral

Title: Proteo-transcriptomics meta-analysis identifies SUMO2 as a promising target in glioblastoma multiforme therapeutics
Authors: Aswani P. Krishna
Sebastian John
Puja Laxmanrao Shinde
Rashmi Mishra
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Glioblastoma
Glioblastoma
Glioblastoma
Published in: Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-021-02279-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Graphical Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Platelet-activating factor acetyl hydrolase IB2 dysregulated cell proliferation in ovarian cancer

Midkine promotes glioblastoma progression via PI3K-Akt signaling

Exosomes from tamoxifen-resistant breast cancer cells transmit drug resistance partly by delivering miR-9-5p

Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance

Identification of autophagy-related risk signatures for the prognosis, diagnosis, and targeted therapy in cervical cancer

Knockdown of GTF2E2 inhibits the growth and progression of lung adenocarcinoma via RPS4X in vitro and in vivo

Keynote webinar | Spotlight on antibody–drug conjugates in cancer